[1] LUU W,SHARPE L J,GELISSEN I C,et al.The role of signalling in cellular cholesterol homeostasis[J].IUBMB Life,2013,65(8):675-684.
[2] RUAN X Z,MOORHEAD J F,TAO J L,et al.Mechanisms of dysregulation of low-density lipoprotein receptor expression in vascular smooth muscle cells by inflammatory cytokines[J].Arterioscler Thromb Vasc Biol,2006,26(5):1150-1155.
[3] MA K L,RUAN X Z,POWIS S H,et al.Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells[J].Am J Physiol Heart Circ Physiol,2007,292(6):H2721-H2728.
[4] MA K L,RUAN X Z,POWIS S H,et al.Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice[J].Hepatology,2008,48(3):770-781.
[5] KUMAR R,BOIM M A.Diversity of pathways for intracellular angiotensin Ⅱ synthesis[J].Curr Opin Nephrol Hypertens,2009,18(1):33-39.
[6] MA K L,VARGHESE Z,KU Y,et al.Sirolimus inhibits endogenous cholesterol synthesis induced by inflammatory stress in human vascular smooth muscle cells[J].Am J Physiol Heart Circ Physiol,2010,298(6):H1646-H1651.
[7] MA K L,LIU J,NI J,et al.Inflammatory stress exacerbates the progression of cardiac fibrosis in high-fat-fed apolipoprotein E knockout mice via endothelial-mesenchymal transition[J].Int J Med Sci,2013,10(4):420-426.
[8] MA K L,LIU J,WANG C X,et al.Activation of mTOR modulates SREBP-2 to induce foam cell formation through increased retinoblastoma protein phosphorylation[J].Cardiovasc Res,2013,100(3):450-460.
[9] MA K L,NI J,WANG C X,et al.Interaction of RAS activation and lipid disorders accelerates the progression of glomerulosclerosis[J].Int J Med Sci,2013,10(12):1615-1624.
[10] MA K L,LIU J,GAO M,et al.Activation of mTOR contributes to foam cell formation in the radial arteries of patients with end-stage renal disease[J].Clin Nephrol,2014,81(6):396-404.
[11] ZHANG Y,MA K L,LIU J,et al.Inflammatory stress exacerbates lipid accumulation and podocyte injuries in diabetic nephropathy[J].Acta Diabetol,2015,52(6):1045-1056.
[12] ZHANG Y,MA K L,LIU J,et al.Dysregulation of low-density lipoprotein receptor contributes to podocyte injuries in diabetic nephropathy[J].Am J Physiol Endocrinol Metab,2015,308(12):E1140-E1148.
[13] LIU J,MA K L,ZHANG Y,et al.Activation of mTORC1 disrupted LDL receptor pathway:a potential new mechanism for the progression of non-alcoholic fatty liver disease[J].Int J Biochem Cell Biol,2015,61:8-19.
[14] GU H M,ZHANG D W.Hypercholesterolemia,low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9[J].J Biomed Res,2015,29(5):356-361.
[15] LAPLANTE M,SABATINI D M.An emerging role of mTOR in lipid biosynthesis[J].Curr Biol,2009,19(22):R1046-R1052.
[16] DAEMEN S,KUTMON M,EVELO C T.A pathway approach to investigate the function and regulation of SREBPs[J].Genes Nutr,2013,8(3):289-300.
[17] BROWN M S,GOLDSTEIN J L.A proteolytic pathway that controls the cholesterol content of membranes,cells,and blood[J].Proc Natl Acad Sci U S A,1999,96(20):11041-11048.
[18] SEVER N,YANG T,BROWN M S,et al.Accelerated degradation of HMG CoA reductase mediated by binding of insig-1 to its sterol-sensing domain[J].Mol Cell,2003,11(1):25-33.
[19] MCPHERSON R,GAUTHIER A.Molecular regulation of SREBP function:the Insig-SCAP connection and isoform-specific modulation of lipid synthesis[J].Biochem Cell Biol,2004,82(1):201-211.
[20] ENGELKING L J,MCFARLANE M R,LI C K,et al.Blockade of cholesterol absorption by ezetimibe reveals a complex homeostatic network in enterocytes[J].J Lipid Res,2012,53(7):1359-1368.
[21] DONG B,WU M,LI H,et al.Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2:mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters[J].J Lipid Res,2010,51(6):1486-1495.
[22] DUAN Y,CHEN Y,HU W,et al.Peroxisome proliferator-activated receptor gamma activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression[J].J Biol Chem,2012,287(28):23667-23677.
[23] SCHULZ R,SCHLUTER K D,LAUFS U.Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9(PCSK9)[J].Basic Res Cardiol,2015,110(2):4.
[24] DEVAY R M,SHELTON D L,LIANG H.Characterization of proprotein convertase subtilisin/kexin type 9(PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2(APLP2)[J].J Biol Chem,2013,288(15):10805-10818.
[25] POIRIER S,MAYER G,POUPON V,et al.Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation:evidence for an intracellular route[J].J Biol Chem,2009,284(42):28856-28864.
[26] ZHANG C P,TIAN Y,ZHANG M,et al.IDOL,inducible degrader of low-density lipoprotein receptor,serves as a potential therapeutic target for dyslipidemia[J].Med Hypotheses, 2016,86:138-142.
[27] SCOTTI E,HONG C,YOSHINAGA Y,et al.Targeted disruption of the idol gene alters cellular regulation of the low-density lipoprotein receptor by sterols and liver x receptor agonists[J].Mol Cell Biol,2011,31(9):1885-1893.
[28] SASAKI M,TERAO Y,AYAORI M,et al.Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms:sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways[J].Arterioscler Thromb Vasc Biol,2014,34(6):1171-1178.
[29] JIANG H,ZHANG J,DU Y,et al.microRNA-185 modulates low density lipoprotein receptor expression as a key posttranscriptional regulator[J].Atherosclerosis,2015,243(2):523-532.
[30] KIM D H,SARBASSOV D D,ALI S M,et al.mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery[J].Cell,2002,110(2):163-175.
[31] PETERSON T R,SENGUPTA S S,HARRIS T E,et al.mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway[J].Cell,2011,146(3):408-420.
[32] AI D,CHEN C,HAN S,et al.Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice[J].J Clin Invest,2012,122(4):1262-1270.
[33] ZHOU D,TAN R J,FU H,et al.Wnt/beta-catenin signaling in kidney injury and repair:a double-edged sword[J].Lab Invest,2015,8(65):675-684.
[34] BORRELL-PAGES M,ROMERO J C,BADIMON L.LRP5 deficiency down-regulates Wnt signalling and promotes aortic lipid infiltration in hypercholesterolaemic mice[J].J Cell Mol Med,2015,19(4):770-777.
[35] GO G W,SRIVASTAVA R,HEMANDEZ-ONO A,et al.The combined hyperlipidemia caused by impaired Wnt-LRP6 signaling is reversed by Wnt3a rescue[J].Cell Metab,2014,19(2):209-220.
[36] TANAKA Y,SHIMADA M,NAGAOKA S.L-Cysteine-induced up-regulation of the low-density lipoprotein receptor is mediated via a transforming growth factor-alpha signalling pathway[J].Biochem Biophys Res Commun,2014,444(3):401-405.
[37] MA K L,RUAN X Z,POWIS S H,et al.Sirolimus modifies cholesterol homeostasis in hepatic cells:a potential molecular mechanism for sirolimus-associated dyslipidemia[J].Transplantation,2007,84(8):1029-1036.
[38] QIN Y W,YE P,HE J Q,et al.Simvastatin inhibited cardiac hypertrophy and fibrosis in apolipoprotein E-deficient mice fed a "Western-style diet" by increasing PPAR alpha and gamma expression and reducing TC,MMP-9,and Cat S levels[J].Acta Pharmacol Sin,2010,31(10):1350-1358.
[39] HARTGERS M L,RAY K K,HOVINGH G K.New Approaches in Detection and Treatment of Familial Hypercholesterolemia[J].Curr Cardiol Rep,2015,17(12):109.
[40] REINER Z.Resistance and intolerance to statins[J].Nutr Metab Cardiovasc Dis,2014,24(10):1057-1066.
[41] KOH K K,SAKUMA I,HAYASHI T,et al.Renin-angiotensin system inhibitor and statins combination therapeutics-what have we learnt?[J].Expert Opin Pharmacother,2015,16(7):949-953.
[42] NORATA G D,TIBOLLA G,CATAPANO A L.PCSK9 inhibition for the treatment of hypercholesterolemia:promises and emerging challenges[J].Vascul Pharmacol,2014,62(2):103-111.
[43] BLOM D J,HALA T,BOLOGNESE M,et al.A 52-week placebo-controlled trial of evolocumab in hyperlipidemia[J].N Engl J Med,2014,370(19):1809-1819.
[44] PIRILLO A,CATAPANO A L.Berberine,a plant alkaloid with lipid- and glucose-lowering properties:from in vitro evidence to clinical studies[J].Atherosclerosis,2015,243(2):449-461.
[45] WU Y,MA K L,ZHANG Y,et al.Lipid disorder and intrahepatic renin-angiotensin system activation synergistically contributes to non-alcoholic fatty liver disease[J].Liver Int,2016[Epub ahead of print].
[46] PETERS S.Inhibition of atherosclerosis by angiotensin II type 1 receptor antagonists[J].Am J Cardiovasc Drugs,2013,13(4):221-224.
[47] ZOJA C,COMA D,GAGLIARDINI E,et al.Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes,which translates into full renoprotection[J].Am J Physiol Renal Physiol,2010,299(5):F1203-F1211. |
